Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|January 2, 2023
Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIIIRitu M Ramamurthy, Martin Rodriguez, Hannah C Ainsworth, et al.
Molecular Therapy. Methods & Clinical Development|October 11, 2021
Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassetteSandeep R P Kumar, Jun Xie, Shilang Hu, et al.
Frontiers in Immunology|March 15, 2024
Directing the migration of serum-free, <i>ex vivo</i>-expanded Vγ9Vδ2 T cellsKiran K Parwani, Gianna M Branella, Rebecca E Burnham, et al.
Molecular Therapy. Methods & Clinical Development|April 8, 2020
Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia ANadia El-Akabawy, Martin Rodriguez, Ritu Ramamurthy, et al.
Blood Advances|February 9, 2021
Molecular coevolution of coagulation factor VIII and von Willebrand factorPhilip M Zakas, Christopher W Coyle, Anja Brehm, et al.
Frontiers in Immunology|May 31, 2022
Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center PathwaySeema R Patel, Taran S Lundgren, Wallace Hunter Baldwin, et al.
Frontiers in Immunology|November 29, 2023
Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemiaGianna M Branella, Jasmine Y Lee, Jennifer Okalova, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 7, 2017
Microfluidic Transduction Harnesses Mass Transport Principles to Enhance Gene Transfer EfficiencyReginald Tran, David R Myers, Gabriela Denning, et al.
Nature Communications|September 28, 2016
Platelet clearance via shear-induced unfolding of a membrane mechanoreceptorWei Deng, Yan Xu, Wenchun Chen, et al.
Frontiers in Immunology|January 23, 2026
Transplanted gene-modified placental cells boost FVIII activity in pediatric sheep without eliciting immunity, toxicity, or adverse eventsBrady Trevisan, Martin Rodriguez, Ritu Ramamurthy, et al.
Pageof 8